human cervical carcinoma cell lines siha  (Procell Inc)

Journal: Oncology Letters

Article Title: Lactylation-based machine algorithm combined with multi-omics analysis to predict prognosis in cervical cancer

doi: 10.3892/ol.2026.15486

Figure Lengend Snippet: HMGN1 inhibition affects the proliferation of cervical squamous cells. (A) mRNA and (B) protein expression levels of HMGN1 in SiHa and HeLa cells following siRNA transfection, compared with the NC. (C) Cell Counting Kit-8 assay assessing the proliferation of SiHa and HeLa cells at 24, 48 and 72 h. (D) Cell cycle distribution of SiHa and HeLa cells after HMGN1 inhibition was analyzed by flow cytometry, including flow cytometry plots and quantitative histograms. *P<0.05, **P<0.01 and ****P<0.001. HMGN1, high-mobility group nucleosome-binding protein 1; NC, non-targeting control; si, small interfering RNA.

Article Snippet: Human cervical squamous cell carcinoma cell lines SiHa (cat. no. HTB-35) and HeLa (cat. no. CRM-CCL-2) were obtained from the American Type Culture Collection and the human keratinocyte cell line HaCaT was obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (SCSP-5091; Beijing, China).

Techniques: Inhibition, Expressing, Transfection, Cell Counting, Flow Cytometry, Binding Assay, Control, Small Interfering RNA

Journal: Cells

Article Title: A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis

doi: 10.3390/cells13030211

Figure Lengend Snippet: Heparanase protein expression, uptake, and processing. ( A ) Compound XII attenuates heparanase levels in PDAC tumors. Nude mice (n = 6/group) s.c. inoculated with Mia PaCa-2 cells were treated with increasing amounts of compound XII (daily injections of 20, 40, or 80 mg/kg) or vehicle alone, as described in . On Day 25, the tumors were resected and the tumor tissue lysates were subjected to Western blotting, applying anti-heparanase (Proteintech 66226-1-ig, Rosemont, IL, USA) and anti-GAPDH polyclonal antibodies. The positive control (HPA 220408 = GS3-linker 58 kDa) was the purified recombinant protein used in the FRET activity assay. The detected endogenous heparanase was presumably the 50 kDa subunit. The molecular weight of standard protein (ladder) was indicated. Treatment with compound XII (20 mg/kg/day) resulted in a marked 50% decrease in the normalized (GAPDH) amount of heparanase. There were no statistical differences between the different doses of compound XII. ( B ) Compound XII inhibits cellular uptake and processing of exogenously added heparanase. Cervical carcinoma cells (SiHa) were left untreated (Con) or were incubated with latent 65 kDa heparanase (1 ug/mL) together with increasing concentrations (1, 5, 10 ug/mL) of compound XII. After 24 h, cultures were washed, and cell lysate samples were subjected to immunoblotting, applying anti-heparanase (upper panel = 50 kDa heparanase subunit) and anti-actin (lower panel) antibodies. The polyclonal anti-heparanase antibodies (ANT-155) were from ProSpec-Tany, TechnoGene Ltd., Ness-Ziona, Israel).

Article Snippet: Human (Mia PaCa-2, BxPC-3, AsPC-1) and mouse (Panc02) pancreatic cancer cell lines, human (MDA-MB-231) and mouse (4T1, Luc4T1) breast carcinoma cell lines, the human MSTO-211H mesothelioma cell line, the human SiHa cervical carcinoma cell line, and the mouse MPC-11 myeloma/plasmacytoma cell line were purchased from the American Type Culture Collection.

Techniques: Expressing, Western Blot, Positive Control, Purification, Recombinant, Activity Assay, Molecular Weight, Incubation